These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38115178)

  • 21. ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.
    Konno H; Lin T; Wu R; Dai X; Li S; Wang G; Chen M; Li W; Wang L; Sun BC; Luo Z; Huang T; Chen Y; Zhang J; Ye Q; Bellovin D; Wan B; Kang L; Szeto C; Hsu K; Kabbarah O
    Cancer Res Commun; 2022 Sep; 2(9):937-950. PubMed ID: 36922936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting.
    Zhou KI; Strickler JH; Chen H
    J Hematol Oncol; 2024 Aug; 17(1):73. PubMed ID: 39183320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
    Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
    Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.
    Xu G; Qian N; Liu Y; Li H; Yang C; Wang J; Wang F; Chen L; Bai G; Xu Q; Pan X; Gao X
    Immunobiology; 2022 Nov; 227(6):152283. PubMed ID: 36198215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
    Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
    Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
    Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
    Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
    Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
    Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.
    Hinner MJ; Aiba RSB; Jaquin TJ; Berger S; Dürr MC; Schlosser C; Allersdorfer A; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Matis L; Olwill SA
    Clin Cancer Res; 2019 Oct; 25(19):5878-5889. PubMed ID: 31138587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.
    Rogers JE; Ajani JA
    Curr Opin Oncol; 2024 Jul; 36(4):308-312. PubMed ID: 38726797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
    Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
    Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Kawazoe A; Hirakawa A; Nakanishi Y; Furuki S; Fukuda M; Ueno Y; Raizer J; Arozullah A
    Cancer Sci; 2023 Apr; 114(4):1606-1615. PubMed ID: 36478334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and comparison of three
    Hu G; Zhu W; Liu Y; Wang Y; Zhang Z; Zhu S; Duan W; Zhou P; Fu C; Li F; Huo L
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2634-2644. PubMed ID: 35347439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of zolbetuximab in pancreatic cancer models.
    Türeci Ӧ; Mitnacht-Kraus R; Wöll S; Yamada T; Sahin U
    Oncoimmunology; 2019; 8(1):e1523096. PubMed ID: 30546962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer.
    Wu J; Chen J; Zhao Y; Yuan M; Chen X; He X; Zhang J; Shao G; Sun Q
    Mol Pharm; 2024 Jul; 21(7):3447-3458. PubMed ID: 38843446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
    Rogers JE; Ajani J
    Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.
    Navarro R; Frago S; Hangiu O; Erce-Llamazares A; Lázaro-Gorines R; Morcillo MA; Rodriguez-Peralto JL; Sanz L; Compte M; Alvarez-Vallina L
    Toxicol Appl Pharmacol; 2024 Jun; 487():116961. PubMed ID: 38740095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies.
    Grizzi G; Venetis K; Denaro N; Bonomi M; Celotti A; Pagkali A; Hahne JC; Tomasello G; Petrelli F; Fusco N; Ghidini M
    J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrasensitive Gastric Cancer Circulating Tumor Cellular
    Fan L; Chong X; Zhao M; Jia F; Wang Z; Zhou Y; Lu X; Huang Q; Li P; Yang Y; Hu Z; Li Q; Zhang X; Shen L
    Anal Chem; 2021 Jan; 93(2):665-670. PubMed ID: 33314914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
    Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
    Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.